Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)

Nenhuma marca registrada encontrada para este princípio ativo.

Não há notas sobre alimentos registradas para este princípio ativo.

• ErenumabMODERADA

  O risco ou a gravidade de efeitos adversos pode aumentar quando Erenumab é usado junto com Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated).

  Visão para especialistas

  The risk or severity of adverse effects can be increased when Erenumab is combined with Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated).

• TheophyllineMODERADA

  A concentração sérica (nível no sangue) de Theophylline pode aumentar quando usado junto com Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated).

  Visão para especialistas

  The serum concentration of Theophylline can be increased when it is combined with Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated).

• 2-MethoxyethanolLEVE

  A eficácia terapêutica de Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) pode diminuir quando usada junto com 2-Methoxyethanol.

  Visão para especialistas

  The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with 2-Methoxyethanol.

• 9-(N-methyl-L-isoleucine)-cyclosporin ALEVE

  A eficácia terapêutica de Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) pode diminuir quando usada junto com 9-(N-methyl-L-isoleucine)-cyclosporin A.

  Visão para especialistas

  The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.

• AbataceptLEVE

  A eficácia terapêutica de Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) pode diminuir quando usada junto com Abatacept.

  Visão para especialistas

  The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Abatacept.

• AbetimusLEVE

  A eficácia terapêutica de Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) pode diminuir quando usada junto com Abetimus.

  Visão para especialistas

  The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Abetimus.

• ActeosideLEVE

  A eficácia terapêutica de Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) pode diminuir quando usada junto com Acteoside.

  Visão para especialistas

  The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Acteoside.

• AdalimumabLEVE

  A eficácia terapêutica de Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) pode diminuir quando usada junto com Adalimumab.

  Visão para especialistas

  The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Adalimumab.

• AfelimomabLEVE

  A eficácia terapêutica de Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) pode diminuir quando usada junto com Afelimomab.

  Visão para especialistas

  The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Afelimomab.

• AldesleukinLEVE

  A eficácia terapêutica de Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) pode diminuir quando usada junto com Aldesleukin.

  Visão para especialistas

  The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Aldesleukin.